Literature DB >> 30500572

Neurocognition and functional outcome in patients with psychotic, non-psychotic bipolar I disorder, and schizophrenia. A five-year follow-up.

Estela Jiménez-López1, Eva María Sánchez-Morla2, Ana López-Villarreal3, Ana Isabel Aparicio4, Vicente Martínez-Vizcaíno5, Eduard Vieta6, Roberto Rodriguez-Jimenez2, José Luis Santos7.   

Abstract

BACKGROUND: Bipolar disorder (BD) and schizophrenia (SZ) are characterized by neurocognitive and functional deficits with marked heterogeneity. It has been suggested that BD with a history of psychotic symptoms (BD-P) could constitute a phenotypically homogeneous subtype characterized by greater neurocognitive and functional impairments, or by a distinct trajectory of such deficits. The aim of this study was to compare the neurocognitive and functional course of euthymic BD-P, euthymic BD patients without a history of psychosis (BD-NP), stabilized patients with schizophrenia and healthy subjects, during a five-year follow-up.
METHODS: Neurocognitive and psychosocial function was examined in 100 euthymic patients with BD (50 BD-P, 50 BD-NP), 50 stabilized patients with schizophrenia (SZ), and 51 healthy controls (HC) at baseline (T1), and after a 5-year follow-up (T2).
RESULTS: The course of both neurocognitive performance and functional outcome of patients with SZ and BD (BD-P and BD-NP) is stable. The profile of neurocognitive impairment of patients with SZ or BD (BD-P and BD-NP), is similar, with only quantitative differences circumscribed to certain domains, such as working memory. The subgroup of patients with BD-NP does not show functional deterioration.
CONCLUSIONS: We have not found evidence of progression in the neurocognitive or psychosocial impairment in any of the three groups of patients, although it cannot be dismissed the possibility of a subset of patients with a progressive course. Other longitudinal studies with larger samples and longer duration are necessary to confirm these findings.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Follow-up; Neurocognition; Psychosis; Psychosocial functioning; Schizophrenia

Mesh:

Year:  2018        PMID: 30500572     DOI: 10.1016/j.eurpsy.2018.11.008

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  6 in total

Review 1.  Neurocognitive impairment and evidence-based treatment options in Bipolar disorder.

Authors:  Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2020-09-23       Impact factor: 3.455

2.  A bottom-up model of functional outcome in schizophrenia.

Authors:  Hongge Luo; Yanli Zhao; Fengmei Fan; Hongzhen Fan; Yunhui Wang; Wei Qu; Zhiren Wang; Yunlong Tan; Xiujun Zhang; Shuping Tan
Journal:  Sci Rep       Date:  2021-04-07       Impact factor: 4.379

Review 3.  Shared and distinct brain fMRI response during performance of working memory tasks in adult patients with schizophrenia and major depressive disorder.

Authors:  Xiuli Wang; Bochao Cheng; Neil Roberts; Song Wang; Ya Luo; Fangfang Tian; Suping Yue
Journal:  Hum Brain Mapp       Date:  2021-08-25       Impact factor: 5.038

4.  The Impact of Sleep on Neurocognition and Functioning in Schizophrenia-Is It Time to Wake-Up?

Authors:  David Kimhy; Luz Ospina; Katie Beck-Felts; Ahmad Fakhoury; Anna E Mullins; Andrew W Varga
Journal:  J Psychiatr Brain Sci       Date:  2022-01-25

5.  Heterogeneity of psychosocial functioning in patients with bipolar disorder: Associations with sociodemographic, clinical, neurocognitive and biochemical variables.

Authors:  Zhengling Ba; Minhua Chen; Jiulan Lai; Yingtao Liao; Hengying Fang; Dali Lu; Yingjun Zheng; Kunlun Zong; Xiaoling Lin
Journal:  Front Psychiatry       Date:  2022-09-20       Impact factor: 5.435

6.  Label-free proteomics differences in the dorsolateral prefrontal cortex between bipolar disorder patients with and without psychosis.

Authors:  Ada M-C Ho; Alejandra Cabello-Arreola; Matej Markota; Carrie J Heppelmann; M Cristine Charlesworth; Aysegul Ozerdem; Gouri Mahajan; Grazyna Rajkowska; Craig A Stockmeier; Mark A Frye; Doo-Sup Choi; Marin Veldic
Journal:  J Affect Disord       Date:  2020-04-08       Impact factor: 4.839

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.